CellTrend GmbH is a specialized biotechnology company and Contract Research Organization (CRO) based in Luckenwalde, Germany, within the Biotechnologiepark. Founded in 1998, the company concentrates on two main business segments: the development and production of Immuno-Assays, particularly Enzyme-Linked Immunosorbent Assays (ELISAs), and providing cell culture-based contract research services (Bioassays) to the pharmaceutical and cosmetics industries.
The company operates with a strong focus on quality, holding certifications such as ISO 9001 and ISO 13485 (for medical devices), and adhering to the guidelines of Good Manufacturing Practice (GMP) as established by the U.S. FDA. This commitment ensures that their products and services meet the stringent requirements necessary for drug development, diagnostics, and pharmaceutical quality control.
Core Business Activities and Focus
CellTrend's core mission is to bridge the gap between pharmacy, biochemistry, and modern biotechnology by providing specialized analytical and cell-based testing capabilities. The services and products are primarily concentrated in the areas of oncology and immunology/inflammation.
1. Contract Research Services (Bioassays)
As a CRO, CellTrend offers customized, complex functional tests using in vitro cultivation of eukaryotic cells. These cell culture systems serve as an ethical and cost-effective compromise for evaluating the toxicity and efficacy of new active agents in the drug and cosmetics development pipelines. The study designs and test systems are individually tailored to meet specific customer needs.
Key areas of expertise and specific functional tests include:
Oncology and Tumor Cell Systems: Offering cell culture test systems for oncological research, including large-scale screening and cytotoxicity assays. This involves utilizing both established cell lines and primary cells (e.g., human tumor cells) to investigate drug effects.
Functional Cell Tests: Performing a variety of complex functional assays that are crucial for drug discovery and mechanism of action studies. These include:
Angiogenesis assays: Testing for the stimulation or inhibition of new blood vessel formation.
Cell Migration assays: Evaluating the movement of cells, a critical factor in cancer metastasis and immune response.
NCI60 Screening: Utilizing a panel of 60 human tumor cell lines for high-throughput screening of compounds.
Immune Cell Functions: Assessing the activity and behavior of immune cells, including immunomodulation.
Cytokine Secretion assays: Measuring the release of signaling molecules by cells in response to stimuli.
Inflammatory Test Systems: Providing cell-based models for research into inflammatory diseases.
2. Immuno-Assays (ELISA) Development and Production
The second major pillar of CellTrend is the development, production, and distribution of antibody-based detection systems, primarily ELISAs. This analytical method is known for its speed, sensitivity, and specificity in binding antibodies to analytes.
Products and Focus Areas:
GPCR Autoantibodies: CellTrend is recognized as a leading company in the development and production of immunoassays for G protein-coupled receptor (GPCR) autoantibodies. GPCR autoantibodies are a group of biomarkers that are increasingly relevant in diagnosing and understanding the pathogenesis of various systemic and autoimmune diseases.
AT1R-Antibody ELISA: A cornerstone product is the ELISA for the determination of auto-antibodies against the Angiotensin-II-Receptor-I (AT1R-Antibody). This assay is a key example of their proprietary technology, which is patented internationally (e.g., European patent number 1393076) and validated according to FDA guidelines.
Diagnostic and Research Test Kits: The company maintains a portfolio of validated diagnostic (in vitro diagnostics for human use) and research-use-only test kits, developed and controlled within their own laboratories.
Clinical Relevance: Their focus on GPCR autoantibodies has direct application in the diagnostics of conditions such as:
Long Covid, where autonomic dysfunction and vascular regulation issues are often linked to GPCR autoantibodies.
Systemic Sclerosis and Transplantation (monitoring rejection).
Products and Services Overview
| Category | Specific Products and Offerings | Description |
| :--- | :--- | :--- |
| Contract Services | Contract Research (CRO) | Sample analysis in CellTrend laboratories using commercial and in-house developed assays. |
| | Contract Manufacturing | Project-specific development and production of new Immuno-Assays (ELISAs), including customized reagents, buffers, and other liquids. |
| | Consulting Services | Expertise offered in GMP consulting and Qualified Person (QP) services for the pharmaceutical and biotech industries. |
| | Bioassays/Cell Culture | Custom-developed and routine cell culture test systems focusing on drug efficacy and toxicity, covering oncology and inflammatory models (e.g., angiogenesis, cytotoxicity, immunomodulation). |
| Diagnostic/Test Kits | AT1R-Antibody ELISA | Patented, validated, ready-to-use ELISA kit for the determination of auto-antibodies against the Angiotensin-II-Receptor-I. |
| | GPCR-Antibody ELISAs | A range of ELISA kits for detecting various G protein-coupled receptor autoantibodies. |
| | In Vitro Diagnostics (human) | Validated diagnostic kits for clinical use. |
| | Research Use Only Kits | Test kits for fundamental research applications. |
| | Fluorescent Cells | Specialty cell lines for specific assay needs. |
In summary, CellTrend GmbH operates as a high-value partner in the life sciences sector, providing critical analytical tools and contract research services that support drug discovery and the advancement of specific autoantibody-based diagnostics.
Please note: This information is generated by AI. For legal use, verify with company sources.
